SURGEPAYS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 USD | +4.05% |
|
+4,826.94% | -.--% |
| 05-13 | SurgePays Q1 Earnings, Revenue Fall | MT |
| 05-13 | Transcript : SurgePays, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 140.5 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Integrated Telecommunications Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 78.29M | - | ||
| +14.74% | 206B | B+ | ||
| +6.26% | 169B | C | ||
| +1.15% | 118B | A- | ||
| -11.90% | 83.4B | B- | ||
| +19.25% | 70.53B | B- | ||
| +4.76% | 61.13B | B | ||
| -5.94% | 50.5B | B | ||
| -29.76% | 39.97B | C | ||
| -18.02% | 38.31B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SURG Stock
- SURG Stock
- Ratings SURGEPAYS
